HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yoshiharu Soga Hitoshi Okabayashi Sakae Enomoto Ichiro Shimada Toshihiko Ban Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soga, Y. Articles by Ban, T. Search for Related Content PubMed PubMed Citation Articles by Soga, Y. Articles by Ban, T. Related Collections Valve disease Related Article

Ann Thorac Surg 2002;73:474-479
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Up to 8-year follow-up of valve replacement with CarboMedics valve

^a Department of Cardiovascular Surgery, Kokura Memorial Hospital, Kitakyushu, Japan
^b Research Department, Kokura Memorial Hospital, Kitakyushu, Japan

Accepted for publication October 17, 2001.

* Address reprint requests to Dr Soga, Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, Japan 606-8507
e-mail: sogakin{at}kuhp.kyoto-u.ac.jp

Background. The aim of this study was to report midterm valve replacement (VR) results with the CarboMedics valve (Sulzer Carbomedics, Austin, TX).

Methods. From 1991 to 1999, 468 patients aged 13 to 76 years (mean 56 years) underwent VR with CarboMedics valve: 239 aortic (A), 167 mitral (M), and 62 A+M or double valve replacement (DVR). Mean follow-up time was 4.4 years; follow-up was 99.1% complete for 2,016 patient-years (PY). The anticoagulation level was targeted to an international normalized ratio of 1.47 to 2.8.

Results. The hospital mortality rate was 1.2%. Actuarial analysis for the entire group at 7 years for survival was 87% ± 2.3%. Freedom from valve-related death was 94% ± 1.9%. Freedom from thromboembolic and bleeding events, respectively, were as follows: for AVR, 82% ± 4.9% (2.4%/PY) and 88% ± 2.9% (1.6%/PY); for MVR, 95% ± 2.1% (0.8%/PY) and 91% ± 3.1% (1.3%/PY); and for DVR, 96% ± 3.2% (0.7%/PY) and 85% ± 9.7% (1.0%/PY). Actuarial freedom from reoperation was 98% ± 1.4%.

Conclusions. The CarboMedics valve can be implanted with satisfactory early mortality and a low incidence of valve-related events even under low-intensity anticoagulation, as shown in a Japanese population.

Related Article

Invited commentary

Jan L. Svennevig
Ann. Thorac. Surg. 2002 73: 479. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				S. Sawaki, A. Usui, T. Abe, M. Yoshikawa, T. Akita, and Y. Ueda Late Mortality and Morbidity in Elderly Patients with Mechanical Heart Valves Asian Cardiovasc Thorac Ann, June 1, 2006; 14(3): 189 - 194. [Abstract] [Full Text] [PDF]

				C. H. Kang, H. Ahn, K. H. Kim, and K.-B. Kim Long-Term Result of 1144 CarboMedics Mechanical Valve Implantations Ann. Thorac. Surg., June 1, 2005; 79(6): 1939 - 1944. [Abstract] [Full Text] [PDF]

				R. Tominaga, K. Kurisu, Y. Ochiai, Y. Tomita, M. Masuda, S. Morita, and H. Yasui A 10-Year Experience With the Carbomedics Cardiac Prosthesis Ann. Thorac. Surg., March 1, 2005; 79(3): 784 - 789. [Abstract] [Full Text] [PDF]

				T. Fukui, S. Takanashi, and Y. Hosoda Coronary Endarterectomy and Stent Removal in Patients With In-Stent Restenosis Ann. Thorac. Surg., February 1, 2005; 79(2): 558 - 563. [Abstract] [Full Text] [PDF]

				G. L. Grunkemeier and Y. Wu "Our complication rates are lower than theirs": Statistical critique of heart valve comparisons J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 290 - 300. [Abstract] [Full Text] [PDF]